Simone Schrodi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simone Schrodi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Philipp
Department of Medicine II, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
2 shared publications - Enrico N. De Toni
Department of Medicine II, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
2 shared publications - Karin Berger
Department of Medicine III, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
2 shared publications - Najib Ben Khaled
Department of Medicine II University Hospital, LMU Munich Munich Germany
2 shared publications - Selina Becht
Department of Medicine III, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
2 shared publications Tobias Weiglein
Department of Medicine III, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
2 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-11
Healthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment — A German Claims Data Study of 2778 Patients
- 2 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-11
Open AccessHealthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment — A German Claims Data Study of 2778 Patients
- Open Access
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths in Germany. National data on the management of HCC remain scarce. Objectives: This study aims to provide an up-to-date overview of clinical characteristics, treatment modalities, and survival outcomes among patients with HCC in Germany. Design: This is a real-world retrospective study using health insurance data from BARMER. Methods: Patients with an HCC diagnosis between 2016 and 2020 were identified in the BARMER database. Comorbidities, anticancer therapies, and treatment pathways of those patients were evaluated using descriptive statistics and survival analysis. Results: A total of 2778 patients with HCC were identified. Of these, 1569 (56.5%) received any anticancer therapy. Transarterial chemoembolization (TACE; 22.3%), liver resection (LR; 20.9%), and systemic therapy (18.9%) were the most frequently used approaches. Survival varied significantly, with liver transplantation (LTx) offering the best outcomes, with a 5-year survival rate of 76%, followed by LR with 40%. Treatments with curative intent, including LTx, LR, and ablation, had a median survival of 40.4 months, compared to 9.7 months for non-curative modalities. Conclusion: In Germany, a substantial proportion of HCC patients remain untreated. Therapies with curative intent, particularly transplantation, provide relevant survival benefits. Improving surveillance efforts could enhance the proportion of patients eligible for these modalities and may represent a critical step toward improved outcomes for patients with HCC.
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessTreatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths in Germany. National data on the management of HCC remain scarce. Objectives: This study aims to provide an up-to-date overview of clinical characteristics, treatment modalities, and survival outcomes among patients with HCC in Germany. Design: This is a real-world retrospective study using health insurance data from BARMER. Methods: Patients with an HCC diagnosis between 2016 and 2020 were identified in the BARMER database. Comorbidities, anticancer therapies, and treatment pathways of those patients were evaluated using descriptive statistics and survival analysis. Results: A total of 2778 patients with HCC were identified. Of these, 1569 (56.5%) received any anticancer therapy. Transarterial chemoembolization (TACE; 22.3%), liver resection (LR; 20.9%), and systemic therapy (18.9%) were the most frequently used approaches. Survival varied significantly, with liver transplantation (LTx) offering the best outcomes, with a 5-year survival rate of 76%, followed by LR with 40%. Treatments with curative intent, including LTx, LR, and ablation, had a median survival of 40.4 months, compared to 9.7 months for non-curative modalities. Conclusion: In Germany, a substantial proportion of HCC patients remain untreated. Therapies with curative intent, particularly transplantation, provide relevant survival benefits. Improving surveillance efforts could enhance the proportion of patients eligible for these modalities and may represent a critical step toward improved outcomes for patients with HCC.